ObesityNCT02177227
Attune With TruMatch TM Personalized Solutions Instruments
A study testing Attune TruMatch (TM) Patient-Specific Instrumentation in people with Obesity and Osteoarthritis, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's at 1 site in Canada.
Trial summary
The purpose of our study is to determine, using a prospective, randomized-controlled trial, the economic viability and clinical outcomes associated with patient-specific instrumentation (PSI) for total knee arthroplasty in an obese patient population. Read more about this study
- Who is it for?
- Ages 20 to 70 years
- Conditions the study is for
- Obesity, Osteoarthritis
- What is being tested?
- Attune TruMatch (TM) Patient-Specific Instrumentation
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 194 participants
- Where
- 1 siteCanada
- Study dates
- Aug 2014to Aug 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- patients with body mass index (BMI; kg/m2) greater than 30 and less than or equal to 50
- Symptomatic knee osteoarthritis deemed most appropriately treated with total knee arthroplasty
- Patient greater than 19 and less than or equal to 70 years of age
- English-speaking
Who cannot join
- History of prior open knee surgery, infection, or previous knee trauma
- Simultaneous bilateral knee arthroplasty
- Underlying dementia, cognitive delay, any disorder, or geographic distance that would preclude the completion of the clinical questionnaires
- Inflammatory arthropathy
- Chronic pain syndrome
- Fibromyalgia
Trial locations and contacts
1 site in 1 country.
Canada1 site
London Health Sciences Centre, University Hospital
London, Ontario, N6A 5A5
About this study
Official title: Attune With TruMatch TM Personalized Solutions Instruments: A Prospective Randomized Controlled Trial Comparing Clinical and Economic Outcomes in Patients With a BMI Between 30 and 50
The purpose of our study is to determine, using a prospective, randomized-controlled trial, the economic viability and clinical outcomes associated with patient-specific instrumentation (PSI) for total knee arthroplasty in an obese patient population.
Read the detailed description
This is a randomized, blinded study. Following REB approval, eligible patients electing to undergo TKA will be identified by either the PI or co-investigators, and approached in an orthopaedic outpatient clinic to discuss enrolment into the study. Patients will be enrolled if they meet the prerequisite inclusion criteria and have signed an informed consent. Patients will then be randomized to undergo a TKA using PSI, or a conventional TKA. The randomization sequence will be computer generated using blocks of five. Preoperative Assessment At baseline, patients will complete a Knee Society Score (KSS), Short-Form 12 (SF-12) Questionnaire, and Western and McMaster University Osteoarthritis Index (WOMAC) questionnaire, and the European Quality of Life Scale Index (EQ-5D). The EQ-5D is a validated, reliable, and feasible outcome measure that provides a utility index. This utility index allows quality adjusted life years to be calculated following an intervention. The questionnaire is a 5-item standardized generic measure of health related quality of life that includes domains of mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each item is scored using a 3-point response scale and each combination of response choices describes a health state (resulting in 243 possible health states). Each health state can then be converted to a utility value ranging from 0 (worst) to 1.0 (best) using existing preference valuation data[22]. It has been valuated in both Canadian and American populations for use in assessing health-related quality of life [23, 24]. We will then calculate each patient's quality-adjusted life year (QALY). QALYs incorporate both length of life and quality of life into a single measure and are calculated by multiplying the utility value by the length of time spent in that health state. Additionally, a clinical assessment will be completed, including knee range of motion, ligamentous assessment, and evaluating for soft tissue contractures. Finally, patients will have 3-foot coronal and sagittal standing radiographs of their lower extremities at our institution. The standing mechanical axis of the involved limb will then be calculated. Skyline views will also be performed as part of the radiographic analysis. In order for appropriate preoperative planning, patients randomized to PSI will undergo a computed tomography (CT) scan of the surgical limb using the TruMatch TM scanning protocol. Following modifications made by the treating surgeon, the personalized patient instruments will be manufactured in standard fashion. Intraoperative Assessment On the day of surgery, patients will receive either a spinal or general anesthetic based on recommendations from an anesthetist, or personal preference. A non-sterile tourniquet will be applied to the operative limb. A mid-line skin incision followed by a medial parapatellar arthrotomy will be used for exposure. The femoral and tibial cuts will be made using conventional instrumentation in the control group, or the TruMatch TM Personalized Solutions Instruments in the treatment group. Soft tissue balancing, including releases and removal of osteophytes, will be performed at the discretion of the surgeon. The Attune TM components will be implanted using cement fixation. At the time of cementing the implants, patients will receive a parenteral weight-based dose of tranexamic acid (20 mg /kg), provided that there are no contra-indications. Prior to closure, patients will receive an intra-articular injection of an anesthetic cocktail. The parapatellar arthrotomy and subcutaneous tissue and skin will be closed in standard fashion. Post-operatively, patients will receive deep-vein thrombosis prophylaxis for 14-days post-operatively. They will also receive 24 hours of post-operative parenteral antibiotics. They will be assessed by physiotherapy, with weight-bearing and range of motion exercises beginning on post-operative day 0. Patients will be discharged from hospital once they have reached appropriate rehabilitative milestones outlined by our institution. Postoperative Assessment Patients will have routine follow-up with their surgeon at 2-, 6-, and 12-weeks, followed by 1-year and every other year thereafter. Three-foot coronal and full-length sagittal standing radiographs, as well as skyline views of the involved knee, will be taken at the 1-year postoperative visit. We will calculate the mechanical axis of the operative limb based on this postoperative radiographic assessment. The patients will complete the KSS, SF-12, WOMAC, and EQ-5D questionnaires at their 6-week, 12-week, and 1-year visits. These outcome questionnaires will be collected prospectively at 5-years and 10-years post-operatively through our institution's database. Assessors of both clinical outcomes and mechanical axis will be blinded to surgical intervention (conventional instrumentation versus PSI TKA). Patients will also receive a health care resource use diary to complete between follow-up intervals in order to collect outpatient direct and indirect costs associated with TKA. Costs Our institution's costs-accounting department will provide information regarding operating room costs, implant costs, and costs associated with routine care such as nursing, medications, and investigations. Physician-related costs will be acquired through Ontario Health Insurance Plan billing protocols. The outpatient cost analysis diary will capture direct, non-medical costs associated with TKA (see Appendix C). The data will be reported in Canadian dollars for the fiscal year in which the in-hospital cost data was derived. A sample database we are currently employing in an unrelated study can be provided if required. Cost-Utility Analysis Incremental Cost-Utility Ratio (ICUR) The ICUR represents the ratio of incremental cost to incremental utility. The incremental cost represents the additional cost of the PSI group compared to the conventional group. The costs will include all direct (operating room, hospital stay, rehabilitation, medications, investigations) and indirect costs (informal care, time lost to productivity). Similarly, the incremental utility is the mean difference in QALY between groups. Net Benefit Regression We will use the net benefit regression (NBR) framework to estimate the incremental net benefit (INB) of PSI [25]. An intervention is considered to be cost-effective if the INB is greater than zero. The net benefit regression method also provides a means to adjust for any potentially confounding factors and therefore allows greater statistical efficiency and provides a more precise estimate of the INB. We will include the following covariates in our regression models: baseline utility score, severity of osteoarthritis, age and number of comorbidities. To characterize the statistical uncertainty around our estimate of INB we will calculate 95% confidence intervals, and a cost-effectiveness acceptability curve (CEAC). Modeling To determine the cost-effectiveness of a new intervention, an economic decision model is appropriate when there are multiple existing sources of evidence to answer a question (e.g. randomized trials, cohort studies, registries, etc.) or to forecast the costs and/or outcomes beyond the follow-up period of the clinical trial. Given that PSI is a relatively new technology, there is no long-term data available to accurately determine the survival of the implant or the rate of revision. To accurately answer this question, we will prospectively follow the cohort long-term to determine survival rates of the implant.
- Conditions
- Obesity, Osteoarthritis
- Being tested
- Attune TruMatch (TM) Patient-Specific Instrumentation
- Keywords
- Total Knee Arthroplasty (TKA), Attune, Primary Total Knee Prosthesis, TruMatch
- Medical subject headings
- Obesity, Osteoarthritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Attune TruMatch (TM) Patient-Specific InstrumentationDevice
Also called TruMatch Patient-Specific Instrumentation
Patients to receive total knee replacement with TruMatch Patient-Specific Instrumentation
| Study group | Role | What they receive |
|---|---|---|
| Total Knee Arthroplasty with PSI | Experimental | Total Knee Replacement with the use of the Attune TruMatch (TM) Patient-Specific Instrumentation Receives: Device: Attune TruMatch (TM) Patient-Specific Instrumentation |
| Total Knee Replacement | No intervention | Total Knee Replacement, as per Standard of Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessment of Possible Change in Radiographic Alignment
Mechanical axis, sagittal alignment and tibial slope are to be assessed.
Measured: Pre-operatively, 6 weeks post-operatively, 1 year post-operatively
Secondary outcomes (3)
Assessment of Possible Change in Peri-operative metrics
Operating room time, hospital length of stay, complications and instances of re-admissions will be assessed.
Measured: 1 year, 5 years and 10 years post-operatively
Patient-completed questionnaires
KSS WOMAC SF-12
Measured: pre-operatively, 6 weeks, 3 months, 1 year and then once each year.
Incremental cost-utility ratio
Operating room time, hospital length of stay, complications and instance of readmission will be assessed.
Measured: 1 year post-operatively, and each year until 10 years post-op
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jun 2014 (estimated)
- Study startAug 2014
- Primary completion6 May 2019
- Study completionAug 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 194 participants (actual)
Sponsor and investigators
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Sponsor type
- University, hospital or other
- Collaborators
- DePuy Orthopaedics, Johnson & Johnson Medical Companies
- Responsible party
- Principal investigator, Edward Vasarhelyi, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Investigators
- Edward M Vasarhelyi, MD, Principal investigator, London Health Sciences Centre
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02177227
- Sponsor's protocol ID
- Attune TruMatch
- Status last verified
- Sep 2026
- First submitted
- 24 Jun 2014
- Last updated
- 18 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Attune With TruMatch TM Personalized Solutions Instruments: A Prospective Randomized Controlled Trial Comparing Clinical and Economic Outcomes in Patients With a BMI Between 30 and 50
- ClinicalTrials.gov ID
- NCT02177227
- Acronym / sponsor ID
- Attune TruMatch
- Conditions
- Obesity, Osteoarthritis
- Keywords
- Total Knee Arthroplasty (TKA), Attune, Primary Total Knee Prosthesis, TruMatch
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 194 participants (actual)
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sUniversity, hospital or other
- Collaborators
- DePuy Orthopaedics, Johnson & Johnson Medical Companies
- Study start
- Aug 2014 (actual)
- Primary completion
- 6 May 2019 (actual)
- Study completion
- Aug 2028 (estimated)
- First posted
- 27 Jun 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of our study is to determine, using a prospective, randomized-controlled trial, the economic viability and clinical outcomes associated with patient-specific instrumentation (PSI) for total knee arthroplasty in an obese patient population.
Detailed description
This is a randomized, blinded study. Following REB approval, eligible patients electing to undergo TKA will be identified by either the PI or co-investigators, and approached in an orthopaedic outpatient clinic to discuss enrolment into the study. Patients will be enrolled if they meet the prerequisite inclusion criteria and have signed an informed consent. Patients will then be randomized to undergo a TKA using PSI, or a conventional TKA. The randomization sequence will be computer generated using blocks of five. Preoperative Assessment At baseline, patients will complete a Knee Society Score (KSS), Short-Form 12 (SF-12) Questionnaire, and Western and McMaster University Osteoarthritis Index (WOMAC) questionnaire, and the European Quality of Life Scale Index (EQ-5D). The EQ-5D is a validated, reliable, and feasible outcome measure that provides a utility index. This utility index allows quality adjusted life years to be calculated following an intervention. The questionnaire is a 5-item standardized generic measure of health related quality of life that includes domains of mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each item is scored using a 3-point response scale and each combination of response choices describes a health state (resulting in 243 possible health states). Each health state can then be converted to a utility value ranging from 0 (worst) to 1.0 (best) using existing preference valuation data[22]. It has been valuated in both Canadian and American populations for use in assessing health-related quality of life [23, 24]. We will then calculate each patient's quality-adjusted life year (QALY). QALYs incorporate both length of life and quality of life into a single measure and are calculated by multiplying the utility value by the length of time spent in that health state. Additionally, a clinical assessment will be completed, including knee range of motion, ligamentous assessment, and evaluating for soft tissue contractures. Finally, patients will have 3-foot coronal and sagittal standing radiographs of their lower extremities at our institution. The standing mechanical axis of the involved limb will then be calculated. Skyline views will also be performed as part of the radiographic analysis. In order for appropriate preoperative planning, patients randomized to PSI will undergo a computed tomography (CT) scan of the surgical limb using the TruMatch TM scanning protocol. Following modifications made by the treating surgeon, the personalized patient instruments will be manufactured in standard fashion. Intraoperative Assessment On the day of surgery, patients will receive either a spinal or general anesthetic based on recommendations from an anesthetist, or personal preference. A non-sterile tourniquet will be applied to the operative limb. A mid-line skin incision followed by a medial parapatellar arthrotomy will be used for exposure. The femoral and tibial cuts will be made using conventional instrumentation in the control group, or the TruMatch TM Personalized Solutions Instruments in the treatment group. Soft tissue balancing, including releases and removal of osteophytes, will be performed at the discretion of the surgeon. The Attune TM components will be implanted using cement fixation. At the time of cementing the implants, patients will receive a parenteral weight-based dose of tranexamic acid (20 mg /kg), provided that there are no contra-indications. Prior to closure, patients will receive an intra-articular injection of an anesthetic cocktail. The parapatellar arthrotomy and subcutaneous tissue and skin will be closed in standard fashion. Post-operatively, patients will receive deep-vein thrombosis prophylaxis for 14-days post-operatively. They will also receive 24 hours of post-operative parenteral antibiotics. They will be assessed by physiotherapy, with weight-bearing and range of motion exercises beginning on post-operative day 0. Patients will be discharged from hospital once they have reached appropriate rehabilitative milestones outlined by our institution. Postoperative Assessment Patients will have routine follow-up with their surgeon at 2-, 6-, and 12-weeks, followed by 1-year and every other year thereafter. Three-foot coronal and full-length sagittal standing radiographs, as well as skyline views of the involved knee, will be taken at the 1-year postoperative visit. We will calculate the mechanical axis of the operative limb based on this postoperative radiographic assessment. The patients will complete the KSS, SF-12, WOMAC, and EQ-5D questionnaires at their 6-week, 12-week, and 1-year visits. These outcome questionnaires will be collected prospectively at 5-years and 10-years post-operatively through our institution's database. Assessors of both clinical outcomes and mechanical axis will be blinded to surgical intervention (conventional instrumentation versus PSI TKA). Patients will also receive a health care resource use diary to complete between follow-up intervals in order to collect outpatient direct and indirect costs associated with TKA. Costs Our institution's costs-accounting department will provide information regarding operating room costs, implant costs, and costs associated with routine care such as nursing, medications, and investigations. Physician-related costs will be acquired through Ontario Health Insurance Plan billing protocols. The outpatient cost analysis diary will capture direct, non-medical costs associated with TKA (see Appendix C). The data will be reported in Canadian dollars for the fiscal year in which the in-hospital cost data was derived. A sample database we are currently employing in an unrelated study can be provided if required. Cost-Utility Analysis Incremental Cost-Utility Ratio (ICUR) The ICUR represents the ratio of incremental cost to incremental utility. The incremental cost represents the additional cost of the PSI group compared to the conventional group. The costs will include all direct (operating room, hospital stay, rehabilitation, medications, investigations) and indirect costs (informal care, time lost to productivity). Similarly, the incremental utility is the mean difference in QALY between groups. Net Benefit Regression We will use the net benefit regression (NBR) framework to estimate the incremental net benefit (INB) of PSI [25]. An intervention is considered to be cost-effective if the INB is greater than zero. The net benefit regression method also provides a means to adjust for any potentially confounding factors and therefore allows greater statistical efficiency and provides a more precise estimate of the INB. We will include the following covariates in our regression models: baseline utility score, severity of osteoarthritis, age and number of comorbidities. To characterize the statistical uncertainty around our estimate of INB we will calculate 95% confidence intervals, and a cost-effectiveness acceptability curve (CEAC). Modeling To determine the cost-effectiveness of a new intervention, an economic decision model is appropriate when there are multiple existing sources of evidence to answer a question (e.g. randomized trials, cohort studies, registries, etc.) or to forecast the costs and/or outcomes beyond the follow-up period of the clinical trial. Given that PSI is a relatively new technology, there is no long-term data available to accurately determine the survival of the implant or the rate of revision. To accurately answer this question, we will prospectively follow the cohort long-term to determine survival rates of the implant.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Total Knee Arthroplasty with PSI | Experimental | Device: Attune TruMatch (TM) Patient-Specific InstrumentationTotal Knee Replacement with the use of the Attune TruMatch (TM) Patient-Specific Instrumentation |
| Total Knee Replacement | No intervention | –Total Knee Replacement, as per Standard of Care |
Who may qualify
- Ages
- 20 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- patients with body mass index (BMI; kg/m2) greater than 30 and less than or equal to 50
- Symptomatic knee osteoarthritis deemed most appropriately treated with total knee arthroplasty
- Patient greater than 19 and less than or equal to 70 years of age
- English-speaking
Key exclusion criteria (6 listed)
- History of prior open knee surgery, infection, or previous knee trauma
- Simultaneous bilateral knee arthroplasty
- Underlying dementia, cognitive delay, any disorder, or geographic distance that would preclude the completion of the clinical questionnaires
- Inflammatory arthropathy
- Chronic pain syndrome
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Attune TruMatch (TM) Patient-Specific InstrumentationAlso: TruMatch Patient-Specific InstrumentationPatients to receive total knee replacement with TruMatch Patient-Specific Instrumentation | Device | Total Knee Arthroplasty with PSI |
Primary outcome
Assessment of Possible Change in Radiographic Alignment
Time frame: Pre-operatively, 6 weeks post-operatively, 1 year post-operatively
Mechanical axis, sagittal alignment and tibial slope are to be assessed.
3 secondary outcomes
Assessment of Possible Change in Peri-operative metrics
Time frame: 1 year, 5 years and 10 years post-operatively
Patient-completed questionnaires
Time frame: pre-operatively, 6 weeks, 3 months, 1 year and then once each year.
Incremental cost-utility ratio
Time frame: 1 year post-operatively, and each year until 10 years post-op
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Obesity
RecruitingObservational study
Early Tracking of Childhood Health Determinants (ETCHED) Study
Diabetes Mellitus, Obesity
Active, not recruiting
Effect of the Thrive AI Health App on Lifestyle Behaviors and Quality of Life
Diabetes Type 2, Overweight or Obesity
Not yet recruitingPhase 3
SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
Obesity
Not yet recruitingObservational study
Assessing the Impact of Perceptions of Unpredictability on Objective Measures of Food Consumption and Metabolism
Healthy Volunteer, Obestity
Not yet recruitingPhase 1/2
Investigating the Effects of 24 Hour LEAP2 Infusion in Individuals With Overweight and Obesity
Obesity & Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Edward M Vasarhelyi, MD principal investigator
London Health Sciences Centre
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Attune TruMatch (TM) Patient-Specific Instrumentation in people with Obesity and Osteoarthritis, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 18 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessment of Possible Change in Radiographic Alignment (time frame: Pre-operatively, 6 weeks post-operatively, 1 year post-operatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2026.